Retatrutide Dosage in Clinical Research | Retatrutide Dr
Dose Levels Studied Across the Trial Program
Retatrutide dosage in clinical research has ranged from 0.5 mg to 12 mg administered once weekly by subcutaneous injection. The specific dose levels studied differ by trial phase and population [5][1][2][9].
Phase 1b (multiple-ascending dose, T2D population, 12 weeks): 0.5 mg, 1 mg, 3 mg, 6 mg, 9 mg, and 12 mg once weekly. The study characterized dose-proportional pharmacokinetics, confirmed the ~6-day half-life, and established early-signal efficacy up to −8.96 kg placebo-adjusted weight loss at 9 mg [5].
Phase 2 obesity (48 weeks): Four active arms — 1 mg, 4 mg, 8 mg, and 12 mg once weekly, each escalated from lower starting doses to manage GI tolerability. Dose-dependent weight loss from −7.2% at 1 mg to −24.2% at 12 mg (48 weeks) [1][2].
Phase 2 type 2 diabetes (36 weeks): Up to 12 mg once weekly, with multiple dose-escalation schedules. Up to 16.9% weight reduction and up to 2.02% HbA1c improvement at highest doses [4].
Phase 3 TRIUMPH-1 (80 weeks): Three active arms — 4 mg, 9 mg, and 12 mg once weekly, each escalated from a 2 mg starting dose with escalation every 4 weeks. Outcomes at 80 weeks: 4 mg −19.0%, 9 mg −25.9%, 12 mg −28.3% mean body weight reduction [9].
Phase 3 TRIUMPH-4 (68 weeks): Two active arms — 9 mg and 12 mg once weekly [10].
Dose-Escalation Schedule
Dose escalation is used across all Retatrutide clinical trials to manage gastrointestinal tolerability during treatment initiation. The standard approach used in the TRIUMPH Phase 3 program initiates treatment at 2 mg once weekly, then escalates every 4 weeks until the assigned maintenance dose (4 mg, 9 mg, or 12 mg) is reached [9].
In Phase 2 trials, escalation schedules varied by cohort but followed the same principle: lower starting doses for a specified number of weeks before titrating to the target maintenance dose [1][4]. Dose-escalation is the mechanism by which nausea and other GI adverse events — most prominent in early treatment weeks — are managed to acceptable rates.
The dose-dependent efficacy signal is strong and monotonic across all studied levels: each step up in maintenance dose produced a larger mean weight reduction in both Phase 2 and Phase 3 data [1][9][11].
How Is Retatrutide Administered?
Subcutaneous injection, once weekly. This is the only route of administration studied in published Retatrutide trials. All Phase 1, Phase 2, and Phase 3 data reported to date were generated using subcutaneous injection [5][1][4][9].
The once-weekly interval is enabled by Retatrutide's approximately 6-day plasma half-life, which results from its C20 fatty diacid conjugation enabling albumin binding [14]. Peak plasma concentration is reached 12–72 hours after injection [14]. No oral formulation of Retatrutide has been reported in published clinical trial data.
Retatrutide Half-Life and Pharmacokinetics
The terminal plasma half-life of Retatrutide is approximately 6 days in human Phase 1b pharmacokinetic data (Urva et al., Lancet 2022) [5]. Pharmacokinetics are dose-proportional across the studied range of 0.5 mg to 12 mg.
The extended half-life is the result of the C20 fatty diacid conjugation attached to the peptide backbone via a lysine-17 linker. This moiety enables non-covalent albumin binding in plasma, dramatically slowing renal clearance and proteolytic degradation — the same albumin-binding strategy used in other once-weekly injectable compounds in the incretin class [14].
Peak plasma concentration is achieved 12–72 hours post-subcutaneous injection. Hepatic metabolism proceeds without CYP450 enzyme involvement, indicating no cytochrome P450-mediated drug-drug interaction risk [14]. Drug-drug interaction studies for non-CYP pathways are ongoing in the TRIUMPH program.
How Long Does Retatrutide Take to Work?
In Phase 2 obesity trial data, meaningful appetite suppression was documented within the first 4 weeks of treatment. Statistically significant body weight reduction was detectable by approximately week 8. Maximum weight loss accrued progressively over the full 48-week Phase 2 treatment period, with no plateau observed at 48 weeks in the 12 mg group — suggesting ongoing efficacy that had not yet reached a ceiling by trial end [22].
In Phase 3 TRIUMPH-1 data (80 weeks), the weight trajectory similarly continued to accrue through the observation window, with the endpoint of approximately 30.3% mean reduction in participants with BMI ≥35 reached at 104 weeks [9].
GI adverse events — the primary tolerability issue — were most prominent during the dose-escalation weeks. As participants reached and maintained their assigned doses, GI event rates declined [3].
Retatrutide is an investigational compound. These onset timelines describe observations in enrolled clinical trial participants. See Retatrutide side effects for the adverse event profile documented in Phase 2 and Phase 3 data.